Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.51 - $26.33
Previous CloseN/A
Volume14.65K
Average Volume (3M)57.93K
Market Cap
$1.27B
Enterprise Value$554.63M
Total Cash (Recent Filing)$280.73M
Total Debt (Recent Filing)€861.47K
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Jul 25, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,493,140
10 Day Avg. Volume110,148
30 Day Avg. Volume57,928
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-5.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.25Price Target Upside43.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Pharvaris News
PremiumCompany Announcements
Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment
PremiumCompany Announcements
Pharvaris Announces Key Resolutions from Annual General Meeting
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressTarget enrollment in the RAPIDe-3 study was reached earlier this year, indicating strong progress in the study.
Financial PositionWith a strong balance sheet and significant catalysts expected, analysts continue to hold a favorable view of the PHVS story.
Market PotentialEncouragement is drawn from the update, continuing to see deucrictibant delivering 'injection-like' efficacy across the on-demand and prophylactic treatment.
Bears Say
Competitive PositioningAnalyst maintains an Underperform rating with a $14 price objective, indicating concerns about PHVS's competitive positioning in the HAE market.
Market CompetitionEkterly, recently approved as the first oral on-demand HAE therapy, will have at least 12 months of market exclusivity before PHVS can enter the market.
Market Entry TimingThe company is likely to enter the market at least 12 months after a competitor, potentially affecting its market share capture.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
8.15% Mutual Funds
0.03% Other Institutional Investors
91.46% Public Companies and
Individual Investors
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $11.51 and its highest was $26.33 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $1.27B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Jul 25, 2025 which is in 2 days.
How were Pharvaris’s earnings last quarter?
Currently, no data Available
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.9.
How many shares outstanding does Pharvaris have?
Pharvaris has 54,493,140 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
Pharvaris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (43.67% Upside)
$34.25 (43.67% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 44.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.84%
12-Months-Change
Fundamentals
Return on Equity
-51.85%
Trailing 12-Months
Asset Growth
-34.29%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Stock 12 Month Forecast
Average Price Target
$34.25
▲(43.67%Upside)